Expand FDMT Menu
FDMT MENU

FDMT Stock Posts


Unusual Option Volume

FDMT 4D Molecular Therapeutics5.23+0.73 (+16.2%)

4D Molecular Therapeutics trades 2,084 contracts. The company has the following event: 43rd Annual Scientific Meeting of the American Society of Retina Specialists on Aug 1, 2025. News: 4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update
View Details...
FDMT stock increases 30.2% after hours.

After Hours Gainer

FDMT 4D Molecular Therapeutics4.50+0.09+2.0%

After Hours:5.86+1.36 (+30.2%)

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

Globe NewswireThu, 31-Jul 4:05 PM
FDMT stock increases 33.3% after hours.

After Hours Gainer

FDMT 4D Molecular Therapeutics4.50+0.09+2.0%

After Hours:6.00+1.50 (+33.3%)

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

Globe NewswireThu, 31-Jul 4:05 PM
FDMT stock declines -3.5% in premarket,

Premarket Decliner

FDMT 4D Molecular Therapeutics11.90-1.60-11.9%

Premarket:11.48-0.42 (-3.5%)

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference

Globe NewswireMon, 23-Sep 8:00 AM
FDMT stock increases 7.0% after hours.

After Hours Gainer

FDMT 4D Molecular Therapeutics18.20-8.55-32.0%

After Hours:19.48+1.28 (+7.0%)

4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity

Globe NewswireWed, 17-Jul 5:00 AM
FDMT stock increases 6.9% after hours.

After Hours Gainer

FDMT 4D Molecular Therapeutics18.20-8.55-32.0%

After Hours:19.46+1.26 (+6.9%)

4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity

Globe NewswireWed, 17-Jul 5:00 AM
Load Earlier Posts
Market Data Delayed 15 Minutes